BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 22069662)

  • 41. Glucosyltransferase-dependent and independent effects of Clostridioides difficile toxins during infection.
    Peritore-Galve FC; Shupe JA; Cave RJ; Childress KO; Washington MK; Kuehne SA; Lacy DB
    PLoS Pathog; 2022 Feb; 18(2):e1010323. PubMed ID: 35176123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.
    Huang J; Kelly CP; Bakirtzi K; Villafuerte Gálvez JA; Lyras D; Mileto SJ; Larcombe S; Xu H; Yang X; Shields KS; Zhu W; Zhang Y; Goldsmith JD; Patel IJ; Hansen J; Huang M; Yla-Herttuala S; Moss AC; Paredes-Sabja D; Pothoulakis C; Shah YM; Wang J; Chen X
    Nat Microbiol; 2019 Feb; 4(2):269-279. PubMed ID: 30510170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function.
    Leslie JL; Huang S; Opp JS; Nagy MS; Kobayashi M; Young VB; Spence JR
    Infect Immun; 2015 Jan; 83(1):138-45. PubMed ID: 25312952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
    Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular Uptake and Mode-of-Action of Clostridium difficile Toxins.
    Papatheodorou P; Barth H; Minton N; Aktories K
    Adv Exp Med Biol; 2018; 1050():77-96. PubMed ID: 29383665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.
    Sambol SP; Merrigan MM; Lyerly D; Gerding DN; Johnson S
    Infect Immun; 2000 Oct; 68(10):5480-7. PubMed ID: 10992443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Clostridium difficile toxin A and B on human T lymphocyte migration.
    Wu D; Joyee AG; Nandagopal S; Lopez M; Ma X; Berry J; Lin F
    Toxins (Basel); 2013 May; 5(5):926-38. PubMed ID: 23645153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
    Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
    Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.
    D'Auria KM; Bloom MJ; Reyes Y; Gray MC; van Opstal EJ; Papin JA; Hewlett EL
    BMC Microbiol; 2015 Feb; 15(1):7. PubMed ID: 25648517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium.
    Yang G; Zhou B; Wang J; He X; Sun X; Nie W; Tzipori S; Feng H
    BMC Microbiol; 2008 Nov; 8():192. PubMed ID: 18990232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
    Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
    Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.
    Sturino JM; Pokusaeva K; Carpenter R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7178-83. PubMed ID: 26149988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.
    Mansfield MJ; Tremblay BJ; Zeng J; Wei X; Hodgins H; Worley J; Bry L; Dong M; Doxey AC
    PLoS Pathog; 2020 Dec; 16(12):e1009181. PubMed ID: 33370413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic Evaluation of Parameters Important for Production of Native Toxin A and Toxin B from
    Aminzadeh A; Jørgensen R
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33801738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
    Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
    PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clostridium difficile Toxin Biology.
    Aktories K; Schwan C; Jank T
    Annu Rev Microbiol; 2017 Sep; 71():281-307. PubMed ID: 28657883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy.
    Koya SK; Yurgelevic S; Brusatori M; Huang C; Diebel LN; Auner GW
    J Surg Res; 2019 Dec; 244():111-116. PubMed ID: 31279995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RstA Is a Major Regulator of Clostridioides difficile Toxin Production and Motility.
    Edwards AN; Anjuwon-Foster BR; McBride SM
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.